CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive ...

Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's ...

In a follow up investigation into the multibillion dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in ...

MEDICS have raised concerns over a drug taken by millions to prevent heart attacks and strokes, claiming key safety data was “misreported” by its manufacturer AstraZeneca.

The twice-daily pill is given to people with acute coronary syndrome -a sudden reduction of blood to the heart-reducing the ...

As generic versions of AstraZeneca’s blockbuster drug ticagrelor prepare to enter the market, The BMJ raises fresh concerns over the integrity of the clinical trials that underpinned its approval.

Choice of statistical models and data integrity are vital A BMJ investigation by Doshi (doi:10.1136/bmj.r1201)1raises concerns about the integrity of two randomised trials with surrogate endpoints ...

In a follow-up investigation into the multibillion-dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in key platelet studies used in its FDA approval.

A new study published in the Journal of American Medical Association showed that switching from ticagrelor to clopidogrel one ...

Long-term maintenance with P2Y12 inhibitor monotherapy after discontinuing dual antiplatelet therapy (DAPT) in patients who’ve undergone PCI seems to reduce MACCE compared with aspirin monotherapy ...